Lilly Buys Psychedelics Biotech

IndianapolisLilly is paying $2.8 billion for a psychedelics startup.

Profits from Lilly’s weight-loss drugs are funding AtaiBeckley’s push to move psychedelic depression treatments toward US regulatory approval, with $1 billion more tied to milestones.

Lilly’s pricing and distribution choices will now shape who can access the treatments.

Sources: STAT